<?xml version="1.0" encoding="UTF-8"?>
<p id="Par45">There is little high-quality evidence of benefit to date for the use of medicinal cannabinoids. The most recent review from the USA National Academies of Sciences, Engineering, and Medicine found substantial evidence for the use of medicinal cannabinoids for treatment of some types of chronic pain, CINV and spasticity in multiple sclerosis in some patients, with moderate evidence for sleep disorders [
 <xref ref-type="bibr" rid="CR10">10</xref>]. Cannabinoid products are licenced for a range of conditions in different countries, with little consistency between countries for indication and dosing [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Whilst cannabinoids may have clinical indication, their use is not without potential for substantial harms, and further research is needed to define their role in medical practice [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR11">11</xref>].
</p>
